Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 See also 2 References

Hydroxyprogesterone heptanoate benzilic acid hydrazone

Add links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Hydroxyprogesterone heptanoate benzilic acid hydrazone
Clinical data

Other names	Hydroxyprogesterone heptanoate benziloylhydrazone; OHPHBH; Hydroxyprogesterone enanthate benzilic acid hydrazone; 17α-Hydroxyprogesterone 17α-heptanoate 3-benzilic acid hydrazone
Routes of administration	Intramuscular injection
Drug class	Progestin; Progestogen; Progestogen ester
Identifiers
CAS Number	120023-34-9
Chemical and physical data
Formula	C₄₂H₅₄N₂O₅
Molar mass	666.903 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O(C(CCCCCC)=O)[C@@](C(C)=O)1CC[C@]([H])2[C@@]([H])3CCC4=C/C(/CC[C@]4(C)[C@@]3([H])CC[C@@]21C)=N/N([H])C(C(O[H])(C1=CC=CC=C1)C1=CC=CC=C1)=O
InChI InChI=KECPQDDETDYRFU-HXKOVYISSA-N Key:1S/C42H54N2O5/c1-5-6-7-14-19-37(46)49-41(29(2)45)27-24-36-34-21-20-32-28-33(22-25-39(32,3)35(34)23-26-40(36,41)4)43-44-38(47)42(48,30-15-10-8-11-16-30)31-17-12-9-13-18-31/h8-13,15-18,28,34-36,48H,5-7,14,19-27H2,1-4H3,(H,44,47)/b43-33+/t34-,35+,36+,39+,40+,41+/m1/s1

Hydroxyprogesterone heptanoate benzilic acid hydrazone (OHPHBH), also known as 17α-hydroxyprogesterone 17α-heptanoate 3-benzilic acid hydrazone, is a progestin medication which was never marketed.^[1]^[2] It is the C3 benzilic acid hydrazoneofhydroxyprogesterone heptanoate (OHPH).^[1]^[2] The medication has a longer duration of action than OHPH when administered by subcutaneous injection in animals.^[1]^[2]

References[edit]

^ ^a ^b ^c Ralph I. Dorfman (3 February 2016). Bioassay. Elsevier. pp. 252–. ISBN 978-1-4832-7276-4.

^ ^a ^b ^c Gleason CH, Parker JM (1959). "The duration of activity of the benziloyl hydrazones of testosterone-17-heptanoate, estrone-3-heptanoate and 17α-hydroxy-progesterone-17-heptanoate". Endocrinology. 65 (3): 508–511. doi:10.1210/endo-65-3-508. ISSN 0013-7227. PMID 13828402.